Please assess the completion status of the following clinical trial:

Trial Title: 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have bipolar I disorder, current episode manic or mixed~* Treated with lithium or valproic acid~Exclusion Criteria:~* Have an unstable medical condition~* Clinically significant laboratory abnormality.~* Have a primary diagnosis other than bipolar I disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine (Type: EXPERIMENTAL): Participants received asenapine as a fast-dissolving sublingual (SL) tablet, given twice daily (BID). On Day 1, participants received asenapine 5 mg, BID. On Days 2 to 84, asenapine was dosed flexibly: BID at either 5 or 10 mg. Asenapine doses were up- or down-titrated based on efficacy, safety, and tolerability.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on Days 1-84 as a fast-dissolving SL tablet, BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).